search
Back to results

Early Albumin Resuscitation During Septic Shock

Primary Purpose

Septic Shock

Status
Completed
Phase
Phase 4
Locations
France
Study Type
Interventional
Intervention
albumin
saline
Sponsored by
Laboratoire français de Fractionnement et de Biotechnologies
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Septic Shock focused on measuring Septic Shock

Eligibility Criteria

18 Years - 80 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Over 18 years old Septic shock < 6 hours Agreement of patients Exclusion Criteria: Allergy to albumin Weight > 120 kg Non septic shock Burned Cirrhosis Albumin perfusion 48 hours before randomization Pregnant women Cardiac dysfunction New York Heart Association (NYHA) 3 or 4 Patients with therapeutic limitation

Sites / Locations

  • Cochin Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Placebo Comparator

Arm Label

Albumin

Saline

Arm Description

Outcomes

Primary Outcome Measures

Mortality, any cause, during the 28 day period after randomization

Secondary Outcome Measures

Evaluation of sequential organ failure assessment (SOFA) score
catecholamine free days
incidence of nosocomial infection
mortality at 90 days
length of ICU hospitalisation
length of total hospitalisation

Full Information

First Posted
May 17, 2006
Last Updated
April 5, 2011
Sponsor
Laboratoire français de Fractionnement et de Biotechnologies
search

1. Study Identification

Unique Protocol Identification Number
NCT00327704
Brief Title
Early Albumin Resuscitation During Septic Shock
Official Title
Multicenter, Prospective, Randomized, Controlled Open Study Albumin 20% Versus Saline
Study Type
Interventional

2. Study Status

Record Verification Date
April 2011
Overall Recruitment Status
Completed
Study Start Date
July 2006 (undefined)
Primary Completion Date
June 2010 (Actual)
Study Completion Date
January 2011 (Actual)

3. Sponsor/Collaborators

Name of the Sponsor
Laboratoire français de Fractionnement et de Biotechnologies

4. Oversight

5. Study Description

Brief Summary
Objective: To determine whether the early administration of albumin as an expander and antioxidant would improve survival on the 28th day for septic shock patients. Design: Prospective, multicenter, randomized, controlled versus saline, stratified on nosocomial infection and center. Setting: 27 Intensive Care Units (ICU) in France Coordinator: Pr J.P. Mira and Dr J. Charpentier - Cochin Hospital- Paris Patients: 800 patients could be included during the first 6 hours of their septic shock.
Detailed Description
The primary outcome: Mortality during the 28 day period after randomization. The secondary outcomes: Evaluation of SOFA score, ventilator-free days, dialysis free days, catecholamine free days, days of hospitalisation, incidence of nosocomial infections. The albuminemia of all patients is requested before the treatment until Day 4 post treatment. The treatment is: Vialebex 20% 100ml every 8 hours during 3 days versus saline 100ml every 8 hours during 3 days. The first patient will be in July 2006, the last patient expected is on July 2009.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Septic Shock
Keywords
Septic Shock

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
794 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Albumin
Arm Type
Active Comparator
Arm Title
Saline
Arm Type
Placebo Comparator
Intervention Type
Drug
Intervention Name(s)
albumin
Other Intervention Name(s)
Vialebex
Intervention Description
albumin 20% 100 ml/8 hours for 3 days
Intervention Type
Drug
Intervention Name(s)
saline
Intervention Description
saline 100 ml/8hours for 3 days
Primary Outcome Measure Information:
Title
Mortality, any cause, during the 28 day period after randomization
Time Frame
day 28
Secondary Outcome Measure Information:
Title
Evaluation of sequential organ failure assessment (SOFA) score
Time Frame
ICU period
Title
catecholamine free days
Time Frame
day 28
Title
incidence of nosocomial infection
Time Frame
ICU period
Title
mortality at 90 days
Time Frame
day 90
Title
length of ICU hospitalisation
Time Frame
ICU discharge
Title
length of total hospitalisation
Time Frame
hospital discharge

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Over 18 years old Septic shock < 6 hours Agreement of patients Exclusion Criteria: Allergy to albumin Weight > 120 kg Non septic shock Burned Cirrhosis Albumin perfusion 48 hours before randomization Pregnant women Cardiac dysfunction New York Heart Association (NYHA) 3 or 4 Patients with therapeutic limitation
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jean P Mira, Professor
Organizational Affiliation
Cochin Hospital
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Julien Charpentier, Doctor
Organizational Affiliation
Hôpital Cochin
Official's Role
Study Director
Facility Information:
Facility Name
Cochin Hospital
City
Paris
ZIP/Postal Code
75 014
Country
France

12. IPD Sharing Statement

Learn more about this trial

Early Albumin Resuscitation During Septic Shock

We'll reach out to this number within 24 hrs